Rhythm Evaluation for AntiCoagulaTion with Continuous Monitoring of Atrial Fibrillation (REACT-AF)

Study to assess whether it is safe and effective to stop oral anticoagulation medications (a blood-thinning medication) during prolonged periods of normal heart rhythm in participants with infrequent episodes of atrial fibrillation (AF) [irregular heartbeat].

In order to participate you must meet the following criteria: 

• Are 22-85 years of age.
• Have a history of non-permanent atrial fibrillation.
• Are on a Direct Oral Anticoagulant (DOAC).
• Are in possession of a smartwatch-compatible smartphone (iPhone that supports the latest iOS) with a cellular service plan and be willing to wear a smartwatch for a minimum of 14 hours a day.

You will be excluded from the study if any of the following criteria apply to you: 

• Are currently being treated with warfarin and unwilling or unable to take a DOAC.
• Are deemed high risk for non-cardioembolic stroke (i.e., significant carotid artery disease).
• Have a tattoo, birthmark, or surgical scar over the wrist area on the side that the AF-sensing smartwatch may be worn.
• Have had a prior stroke (ischemic or hemorrhagic) or transient ischemic attack.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.